A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

New England Journal of Medicine

Volumn 334, Issue 5, 1996, Pages 296-300

  Barst, Robyn J ^a   Rubin, Lewis J ^b   Long, Walker A ^c   Mcgoon, Michael D ^d   Rich, Stuart ^e   Badesch, David B ^f   Groves, Bertron M ^f   Tapson, Victor F ^g   Bourge, Robert C ^h   Brundage, Bruce H ⁱ   Koerner, Spencer K ^j   Langleben, David ^k   Keller, Cesar A ^l   Murali, Srinivas ^m   Uretsky, Barry F ^m   Clayton, Linda M ⁿ   Jöbsis, Maria M ⁿ   Blackburn Jr , Shelmer D ⁿ   Shortino, Denise ⁿ   Crow, James W ⁿ  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k MCGILL UNIVERSITY   (Canada)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

ⁿ Burroughs Wellcome Co   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0030031888     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/nejm199602013340504     Document Type: Review

References (35)

1. Rich S, Dantzker DR, Ayres SM, et al Primary pulmonary hypertension. a national prospective study. Ann Intern Med 1987;107:216-23
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115.343-9.
3. Rubin LJ. Primary pulmonary hypertension. Chest 1993,104:236-50.
4. Reeves JT, Groves BM, Turkevich D The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986;134: 342-6.
5. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension Am Rev Respir Dis 1989;140 1623-30.
6. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
7. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986;89: 497-503.
8. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
9. Reitz BA, Wallwork JL, Hunt SA, et al Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982;306.557-64
10. Pasque MK, Trulock EP, Kaiser LR, Cooper JD Single-lung transplantation for pulmonary hypertension three-month hemodynamic follow-up. Circulation 1991,84:2275-9.
11. Glanville AR, Burke CM, Theodore J, Robin ED Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 1987;91:675-81.
12. Chapelier A, Vouhë P, Macchiarini P, et al. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1993;106:299-307.
13. Bando K, Armitage JM, Paradis IL, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994,108.1056-65.
14. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE Prostacyclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension. Circulation 1982;66:334-8.
15. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-91.
16. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994,121:409-15.
17. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
18. Guyatt GH, Sullivan MJ, Thompson PJ. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
19. Hunt SM, McEwen J, McKenna SP The Nottingham Health Profile user's manual: measuring health status. London: Croom Helm, 1986.
20. Guyatt GH, Norgradi S, Halcrow S, Singer J, Sullivan MJJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101-7.
21. Feinstein AR, Fisher MB, Pigeon JG Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989,64:50-5
22. Quade D. Rank analysis of covariance. J Am Stat Assoc 1967,62:1187-200.
23. Cox DR, Oakes D. Analysis of survival data. London. Chapman & Hall, 1984.
24. Hodges JL Jr, Lehmann EL Estimates of location based on rank tests. Ann Math Stat 1963;34:598-611.
25. Wilcoxon F Individual comparisons by ranking methods. Biometrics 1945; 1:80-3.
26. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951,11 686-705.
27. 2) in the cat. Circ Res 1979;45:404-9.
28. 2). Prostaglandins Med 1979,3:105-17.
29. Lefer AM, Ogletree ML, Smith JB, et al Prostacyclin, a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 1978,200:52-4.
30. Balint GA, Varró V Cytoprotective effect of prostacyclin and protein synthesis Acta Physiol Hung 1983;61:115-22.
31. Konturek SJ, Brzozowski T, Piastucki I, et al. Role of mucosal prostaglandins and DNA synthesis in gastric cytoprotection by luminal epidermal growth factor. Gut 1981;22:927-32.
32. Borda LS, Cangas L, Gimeno MF, Gimeno AL An adrenergic participation subserving a positive inotropism and chronotropism of prostacyclin on isolated rat atria Experientia 1979;35:529-30.
33. Data JL, Molony BA, Meinzinger MM, Gorman RR Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3′:5′-cyclic monophosphate levels. Circulation 1981;64:4-12.
34. Graham DR, Keldermans MM, Klemm LW, Semenza NJ, Shafer ML. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991,91 95S-100S.
35. Herfindal ET, Bernstein LR, Wong AF, Hogne VW, Darbiman JA. Complications of home parenteral nutrition. Clin Pharm 1992;11.543-8.